Epigenetic drugs in cognitive disorders.
1Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore 632 002, India. jpeedi@cmcvellore.ac.in.
Current Pharmaceutical Design
|July 30, 2013
Summary
Epigenetic drugs offer a novel approach to treating cognitive disorders by reversing gene expression changes. These therapies show promise for improving patient outcomes in conditions like Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Cognitive disorders significantly impact brain function, with current treatments offering limited efficacy and primarily symptomatic relief.
- Emerging evidence implicates epigenetic alterations in gene expression as a key factor in the development of cognitive disorders.
Purpose of the Study:
- To explore the potential of epigenetic drugs in treating cognitive disorders.
- To focus on the application of epigenetic drugs in Alzheimer's disease, Huntington's disease, and Parkinson's disease.
Main Methods:
- Review of current research on epigenetic mechanisms in cognitive disorders.
- Focus on two main classes of epigenetic drugs: histone deacetylase (HDAC) inhibitors and drugs targeting DNA methylation.
Main Results:
- Epigenetic drugs represent a new class of therapeutics designed to reverse aberrant epigenetic modifications.
- Histone deacetylase (HDAC) inhibitors and DNA methylation inhibitors are primary examples of epigenetic drugs under investigation.
Conclusions:
- Epigenetic drugs hold significant potential for improving the clinical management of patients suffering from cognitive disorders.
- Targeting epigenetic changes offers a promising avenue for developing more effective treatments for neurodegenerative diseases.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...